<DOC>
	<DOCNO>NCT01911221</DOCNO>
	<brief_summary>The study evaluate immunogenicity safety rMenB+OMV NZ adult population potentially risk meningococcal disease ( e.g . lab worker ) .</brief_summary>
	<brief_title>A Phase 3b , Single-Center , Open-label Study Assess Immunogenicity Safety Novartis Meningococcal B Recombinant Vaccine When Administered 0 , 2-Month Schedule Healthy At-Risk Adults Aged 18 65 Years Inclusive .</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . 18 65 year age inclusive give write informed consent time enrollment ; 2. Who available visit schedule study ( i.e. , plan leave area end study period ) ; 3 . In good health determine medical history , physical examination clinical judgment investigator ; 4. Who might routinely expose culture N. meningitidis serogroup B . Sponsor 's employee consider eligible participate trial per inclusion criterion . 1 . Pregnancy nursing ( breastfeed ) mother ; 2 . Females reproductive age use plan use acceptable birth control measure , 3 month duration study . Oral , inject implanted hormonal contraceptive , diaphragm , condom , intrauterine device sexual abstinence consider acceptable form birth control . If sexually active subject must use one accepted birth control method least 60 day prior study entry ; 3 . Any serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) ; 4 . Individuals history progressive severe neurologic disorder , seizure disorder . A single episode febrile convulsion exclusion criterion ; 5 . History serogroup B meningococcal vaccine administration ; 6 . Previous know suspected disease cause N. meningitidis ; 7 . History severe allergic reaction previous vaccination , hypersensitivity component vaccine ; 8 . Known suspected autoimmune disease impairment/alteration immune system result ( example ) : Receipt chronic immunosuppressive therapy Receipt chronic immunostimulants Immune deficiency disorder , know HIV infection 9 . Subjects able comprehend follow require study procedure whole period study ; 10 . History illness/condition , opinion investigator , might interfere result study pose additional risk subject due participation study ; 11 . Any significant chronic infection ; 12 . Known bleed diathesis condition may associate prolonged bleeding time ; 13 . Family member household member research staff ; 14 . Participation another clinical trial within last 30 day plan study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Meningococcal disease ,</keyword>
	<keyword>Adults</keyword>
</DOC>